TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01034631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNC105P
Description: BNC105P, up to 16 mg/m\^2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BNC105P
Description: BNC105P, up to 16 mg/m\^2
Study: NCT00874107

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG® Injection
Description: 4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Bevacizumab
Description: 15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.

Intervention type: DRUG
Group type: OTHER
Intervention: Paclitaxel
Description: 200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Carboplatin
Description: AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
Study: NCT03186495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
Study: NCT03322566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administered intravenously every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: Investigator selected one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin, depending on histology.
Study: NCT02715063

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Plus: High Intensity Interval + Resistance Training
Description: Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual clinical care
Description: Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
Study: NCT00335023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red blood cell transfusion
Description: At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
Study: NCT01213706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration (WBPA)
Description: Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Whole Body Periodic Acceleration (WBPA)
Description: Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham WBPA
Description: The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
Study: NCT03322566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered orally twice daily.
Study: NCT01213706

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham WBPA
Description: The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
Study: NCT04517331

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block-single injection
Description: The blocks were performed at the T3-T4 level bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block-double injection
Description: The blocks were performed at both T2-T3 and T4-T5 levels bilaterally to block the dermatomes between the T2 and T6 levels (breast innervation area).
Study: NCT01368406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: wellness program
Description: 12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
Study: NCT03256812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ICT-based ECG monitoring
Description: Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Holter monitoring
Description: 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
Study: NCT02434718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: As described in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: As described in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: As described in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aducanumab
Description: As described in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV administration of 0.9% sodium chloride
Study: NCT03257891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: Cabazitaxel will be administered every 21 days
Study: NCT00070304

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
Study: NCT02434718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV administration of 0.9% sodium chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV administration of 0.9% sodium chloride
Study: NCT03186495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
Study: NCT00070304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Description: Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
Study: NCT03927937

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AUTOTRANSPLANTATION TOOTH
Description: Tooth with imposible prognosis is replace with a healthy tooth from the same patient.
Study: NCT03200873

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
Study: NCT03158688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.
Study: NCT02434718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV administration of 0.9% sodium chloride
Study: NCT01560403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 0.05 mg/kg/day subcutaneously taken once per day for 12 months
Study: NCT03551132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise test
Description: Fat mass, Functional autonomy, muscular strength, quality of life questionnaire
Study: NCT01182610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 9mg/kg on Days 1, 22, and 43

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 200mg/m2 on Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC=6 on Days 1 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5FU 225mg/m2/day on Days 1-15 and 22-36
Study: NCT00752180

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Wosulin R
Description: Total dose per subject will be 0.3 IU/Kg given Subcutaneously.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Actrapid
Description: Total dose per subject will be 0.3 IU/kg given Subcutaneously.
Study: NCT04218695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Description: Antibiotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 50cc intravenous once daily
Study: NCT03255642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin 2mg
Description: 4 weeks of 2mg prolonged release melatonin (Circadin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ClonazePAM 0.5 MG
Description: 4 weeks of 0.5mg clonazepam (Rivotril)
Study: NCT04386733

Intervention type: OTHER
Intervention: no intervention, it was an observational study which looked at the reasons for surgical cancellations
Description: the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations

Intervention type: OTHER
Intervention: no intervention, it was an observational study which looked at the reasons for surgical cancellations
Description: the investigators observed how many patients had their surgeries cancelled and analysed the reasons of these cancellations
Study: NCT00464672

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine
Description: Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator influenza vaccine
Description: Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
Study: NCT00641472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension
Description: 0.5mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast Sodium
Description: 4mg or 5mg
Study: NCT02093533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Study: NCT01063023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen®
Description: Tablets, Oral, 1 Tablet, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen®
Description: Tablets, Oral, 1 Tablet, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri-Cyclen®
Description: Tablets, Oral, 1 Tablet, once daily
Study: NCT03158688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Commercially available oral and IV formulas were obtained by investigative sites. Amgen supplied IV or PO dexa for some countries (Poland, Hungry, Romania, Bulgaria, Korea). Dosage modification rules applied based on participant age (participants \> 75 years were given lower doses), dexa-related toxicities, and discontinuation of carfilzomib.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab was supplied as a concentrated solution for infusion in single-use vials.
Study: NCT01063023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-650032
Description: Tablets, Oral, 600 mg, BID
Study: NCT01230346

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Telephone intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Telephone intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention
Description: Telephone intervention
Study: NCT02454244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ART with Mindfulness
Description: 1. Introduction of ART with Mindfulness. Visualization of 100% recovery~2. Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation~3. The ART. Breaking the negative thoughts related to the illness. Walking meditation~4. Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation~5. Mindfulness and self-compassion. Kindly awareness meditation~6. The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation~7. Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities~8. Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values~9. The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self~10. Return to regular life. Mindfulness practice

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Compassion
Description: 1. Introduction.Definition of Compassion~2. Self-Esteemed and Compassion~3. Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions~4. Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability~5. Love,affection and self-compassion.How participants connect with the suffering of others~6. Equanimity~7. Forgiveness~8. Interdependence. Gratitude.Affection to unknown people~9. Developing affection and empathy.Empathy and burn out~10. Review of the practices and meditations

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation
Description: 10 sessions based on relaxation techniques as active comparator intervention
Study: NCT03087539

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Abciximab

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00763282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management (SM)
Description: Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Description: Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
Study: NCT03158688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib for infusion was supplied as a lyophilized, sterile product in single-use vials. The lyophilized product was reconstituted with preservative-free sterile water for injection, the reconstituted solution contained carfilzomib 2 mg/mL. IV injections lasted approximately 30 minutes.~Dose could be modified based on a \>20% change in body weight or toxicity.
Study: NCT03063216

Intervention type: PROCEDURE
Intervention: intraocular lens implantation
Description: 1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation

Intervention type: PROCEDURE
Intervention: intraocular lens implantation
Description: 1）Pediatric cataract patients with intraocular lens implantation and those without intraocular lens implantation；2）Traumatic cataract patients with intraocular lens implantation and those without intraocular lens implantation
Study: NCT00710619

Intervention type: DRUG
Intervention: activated recombinant human factor VII
Description: This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors

Intervention type: DRUG
Intervention: Feiba VH
Description: This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
Study: NCT03465865

Intervention type: DEVICE
Intervention: optical coherence tomography
Description: optical coherence tomography enables diagosis of macular structures and therefore provides information on macular hole closure.
Study: NCT03884673

Intervention type: DRUG
Intervention: DTG+ 3TC
Description: It is a simplified therapy regimen study of dolutegravir combined with lamivudine for HIV-1 infected patients in the real world of China.
Study: NCT01101126

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary disease management
Description: Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
Study: NCT05630456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Receving feedback
Description: Receving regular feedback from a health provider

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No regular feedback
Description: No regular feedback from a health provider
Study: NCT01748656

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVAPS
Description: IVAPS mode (RESMED Stelar 150) during 1 night

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AVAPS
Description: AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
Study: NCT00398814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.